Reported Saturday, Anavex Announces 4-Year Data For Oral Blarcamesine In Early Alzheimer's Disease, Showing Sustained Cognitive And Functional Benefit

-3.62%

Anavex Life Sciences Corp.

AVXL

0.00

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference

Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer's disease

Blarcamesine exhibited a favorable safety profile with no treatment-related deaths

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.